齐齐哈尔市无偿献血者血液HBV、HCV、HIV酶免检测联合核酸检测结果分析

摘要

目的：探讨酶免检测联合核酸扩增检测2016年齐齐哈尔地区无偿献血人群HBV、HCV、HIV-I和HIV-2感染的收益情况。方法对2016年齐齐哈尔地区无偿献血者血液标本进行HBV、HCV、HIV（1+2型）感染性标志物的筛查。结果EIA检测HBsAg、抗-HCV、抗-HIV均为阴性的合格血液共13716份/14097份。NAT检测呈反应性19份/13716份，反应性率为1.39‰。19例NAT检测反应性标本中11例为NAT拆分检测病毒核酸反应性且11例均为HBV DNA反应性。结论应用核酸扩增检测能有效提高输血安全，降低输血传播相关病毒的风险；而献血人群中检出核酸反应性的标本主要为HBV DNA反应性而HBsAg无反应性。%Objective To investigate the effect of EIA and NAT on screening HBV, HCV, HIV-1 and HIV-2 in volunteer-donators in Qiqihar in 2016. Methods The HBV, HCV and HIV (1+2 type) were screened in volunteer-donators in Qiqihar in 2016. Results The results of EIA showed that the negative of HBsAg, anti-HCV and anti-HIV were 13 716 samples in 14 097. The results of NAT showed that the reactivity rate of HBsAg, anti-HCV and anti-HIV were 19 samples in 13 716, the reactivity rate was 1.39‰. 11 in 19 NAT reactivity samples were NAT split testing reactivity of the viral nucleic acid, and all were HBV DNA reactivity. Conclusion NAT can improve the blood transfusion safety and reduce the risk of transfusion related viruses, the nucleic acid reactivity was HBV DNA, no was HBsAg.